Managing moderate-to-severe plaque psoriasis has shifted dramatically with targeted monoclonal antibodies. However, clinical trial results do not always reflect routine patient administration patterns. Evaluating biologic adherence in psoriasis is crucial because poor adherence directly compromises clinical efficacy and treatment persistence. Recently, a multicenter cohort study evaluated real-world adherence to interleukin inhibitors, highlighting remarkably high compliance rates among treated patients. Consequently, understanding these findings enables clinicians to optimize long-term dermatologic management and design supportive patient-retention strategies across routine hospital and ambulatory care practices.

Clinical Importance of Biologic Adherence in Psoriasis

Therapeutic success in chronic inflammatory skin diseases depends fundamentally on consistent medication intake. Biologics targeting interleukin-17, interleukin-23, and interleukin-12/23 offer superior clearance compared to traditional systemic agents. Nevertheless, inconsistent drug administration often causes secondary loss of response, unnecessary dose escalation, or premature drug switching. In addition, irregular dosing patterns foster antidrug antibody production, which permanently blunts biologic efficacy. Clinicians frequently assess treatment persistence, yet persistence measures only continuous treatment duration without verifying timely dosing. In contrast, adherence measures whether patients actually receive their prescribed doses at the scheduled therapeutic intervals. Therefore, clinicians must measure adherence systematically to interpret real-world therapeutic outcomes accurately. When patients miss doses or delay pharmacy pickups, disease flare-ups inevitably emerge. Furthermore, high adherence lowers overall healthcare utilization by preventing acute psoriasis flares and reducing emergency visits. Ultimately, systematic tracking ensures that patients achieve sustained skin clearance and avoid preventable secondary biologic failures.

Multicenter Cohort Design and Adherence Metrics

The multicenter observational investigation analyzed adult patients receiving biologic therapy across three public healthcare facilities, including one tertiary center and two regional hospitals. Researchers evaluated individuals who maintained therapy for at least four continuous months between December 2009 and October 2025. Specifically, the study examined interleukin-17 inhibitors, interleukin-23 inhibitors, and the interleukin-12/23 blocker ustekinumab. To quantify medication adherence rigorously, investigators calculated the medication possession ratio from hospital pharmacy dispensation logs. In addition, the medication possession ratio reflects the proportion of days a patient possesses medication relative to the intended treatment interval. Investigators defined standard satisfactory adherence as a medication possession ratio of at least 80%. Moreover, they established a stricter threshold of at least 90% to identify excellent adherence. Multivariable logistic regression models with patient-level clustering accounted for individuals receiving repeated biologic courses over time. Consequently, this robust analytical methodology minimized statistical confounding while capturing granular, long-term dispensation trends across diverse hospital environments.

Key Real-World Findings Across Interleukin Inhibitor Classes

The study examined 423 unique patients representing 626 distinct treatment courses over the comprehensive observation period. Overall, the cohort demonstrated exceptional treatment compliance, achieving a mean adherence rate of 94.5%. Furthermore, 97.4% of treatment courses reached or exceeded the conventional 80% adherence benchmark. Additionally, 78.8% of courses achieved excellent adherence with a medication possession ratio of 90% or greater. These compelling results indicate that patients maintain rigorous adherence when public hospital pharmacies monitor medication delivery. Notably, adherence rates remained consistently high across all three biologic classes, underscoring significant patient satisfaction and tolerability. When patients experience meaningful cutaneous relief without debilitating side effects, their motivation to maintain treatment schedules increases substantially. Consequently, modern cytokine-targeted therapies exhibit much higher adherence than earlier self-administered systemic medications or messy topical regimens. Therefore, these impressive statistics confirm that structured hospital dispensation frameworks effectively support chronic biologic management.

Predictors of Excellent Adherence: Age, Sex, and Regimen Spacing

Multivariable logistic regression analysis identified several independent variables significantly linked to excellent adherence. Specifically, older age independently increased the likelihood of achieving a medication possession ratio above 90%. Older individuals often maintain regular daily routines and prioritize medical appointments more consistently than younger, working-age cohorts. Similarly, female sex emerged as a statistically significant predictor of superior adherence. Female patients frequently demonstrate proactive self-care behaviors and adhere more strictly to medical instructions in chronic skin diseases. Importantly, therapy with interleukin-23 inhibitors was independently associated with achieving excellent adherence compared to other biologic classes. Interleukin-23 inhibitors provide durable skin clearance with convenient, extended maintenance dosing intervals, typically every eight to twelve weeks. In contrast, interleukin-17 inhibitors often require monthly or biweekly injections after induction. Therefore, less frequent dosing schedules reduce treatment burden, minimize injection fatigue, and prevent missed doses. As a result, selecting agents with spaced dosing intervals directly improves patient compliance.

Practical Implications for Indian Dermatologists and Healthcare Systems

These real-world findings offer valuable lessons for dermatologists and rheumatologists practicing in India. Although private out-of-pocket expenditure often dictates biologic choices in Indian settings, adherence remains critical for maximizing clinical investments. When patients invest in advanced targeted biologics, missed doses cause disease relapses that compromise economic efficiency. Therefore, clinicians must select therapeutic regimens that align with patient lifestyle, travel constraints, and financial resources. Furthermore, introducing centralized tracking systems and digital reminder applications can emulate the high adherence seen in hospital-dispensed cohorts. Because interleukin-23 inhibitors permit extended intervals of eight to twelve weeks, they offer distinct logistical advantages for rural or traveling Indian patients. In addition, dermatologists should counsel younger male patients proactively, as this demographic displays lower adherence tendencies. By integrating structured patient education, proactive follow-up schedules, and convenient injection intervals, Indian clinicians can replicate high adherence rates and achieve lasting disease control in moderate-to-severe psoriasis.

Frequently Asked Questions

How is medication adherence defined and calculated in biologic psoriasis therapy?

Researchers calculate biologic adherence primarily through the medication possession ratio. This metric divides the total days for which a patient possesses dispensed medication by the total elapsed observation days. Clinicians typically define satisfactory adherence as an index of 80% or greater. Furthermore, an adherence ratio of 90% or above reflects excellent real-world compliance, ensuring that therapeutic drug concentrations remain optimal.

Why do interleukin-23 inhibitors show higher adherence rates than other biologics?

Interleukin-23 inhibitors achieve higher adherence largely because they require infrequent maintenance administration, usually once every eight or twelve weeks. Consequently, patients experience substantially less injection fatigue and fewer schedule disruptions. Moreover, these targeted agents deliver sustained, high-level skin clearance. This consistent clinical symptom relief reinforces patient confidence and directly encourages individuals to collect their prescribed injections reliably across long-term maintenance therapy courses.

How does medication adherence directly influence treatment persistence?

Medication adherence and persistence represent distinct yet closely related clinical parameters. Adherence reflects whether patients administer medications according to prescribed timing schedules, whereas persistence measures the overall duration of continuous treatment. Inadequate adherence frequently triggers secondary loss of response, neutralizing antibody generation, and premature drug discontinuation. Conversely, excellent adherence maintains optimal therapeutic serum concentrations, preventing acute disease flares and sustaining long-term biologic persistence.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or establish a doctor-patient relationship. Healthcare professionals should make clinical decisions based on individual patient assessments and valid medical guidelines. While efforts have been made to ensure accuracy, the authors and publishers accept no liability for errors or omissions. Refer to the latest local and national guidelines for clinical practice.

References

1. Calvo-Arbeloa M et al. Real-world adherence to biologic therapies targeting interleukin 17, interleukin 23 and ustekinumab in moderate-to-severe psoriasis: A multicenter cohort study. Farm Hosp. 2026 Oct 14. doi: undefined. PMID: 42875349.
2. Piragine E, Petri D, Martelli A, et al. Adherence and Persistence to Biological Drugs for Psoriasis: Systematic Review with Meta-Analysis. J Clin Med. 2022;11(6):1506.
3. Leonardi C, et al. Real-World Biologic Adherence, Persistence, and Monotherapy Comparisons in US Patients with Psoriasis: Results from IBM MarketScan Databases. Adv Ther. 2022;39(7):3245-3260.
4. Armstrong AW, Puig L, Joshi A, et al. Comparison of Biologic Treatment Persistence and Adherence in Patients with Psoriasis. J Am Acad Dermatol. 2021;85(3):614-623.